Can Fite BioPharma Ltd (CANF) News

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

Orphan Drug Designation has been granted lately by US FDA RAMAT GAN, Israel, Nov. 11, 2024 (GLOBE NEWSWIRE...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia

Namodenoson is an oral drug with a proven favorable safety profile RAMAT GAN, Israel, Nov. 04, 2024 (GLOBE...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson

Data Reported by Can-Fite Veterinary Partner Vetbiolix who already exercised its option for a full license deal...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer

RAMAT GAN, Israel, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:...

Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29

RAMAT GAN, Israel , Oct. 07, 2024 (GLOBE NEWSWIRE) --  Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis

The agreement has been signed upon successful conclusion of a clinical study in dogs with osteoarthritis RAMAT...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health

Study will aim to establish safety and clinical efficacy PETACH TIKVA, Israel, Sept. 16, 2024 (GLOBE...

Form EFFECT - Notice of Effectiveness

Form 424B3 - Prospectus [Rule 424(b)(3)]